Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

HIFU

New study suggests a more accurate system for early detection, treatment of prostate cancer

A new study may lead to a more accurate system for early detection, diagnosis, and treatment of prostate cancer. It’s a promising development given prostate cancer is the second most common cancer among men worldwide, responsible for 308,000 deaths in 2012 and estimated to take 26,120 lives in the U.S. alone in 2016.


New research coauthored by Brigham Young University researchers may lead to a more accurate system for early detection, diagnosis, and treatment of prostate cancer.

The new study, published this week in Proceedings of the National Academy of Sciences, details a computer model that uses medical images to reproduce the growth patterns of prostate cancer on the anatomy of a patient’s prostate.

This type of mathematical modeling and simulation of disease (aka predictive medicine) can lead to personalized treatment and more accurate forecasting of clinical outcomes.

“There is a lot of room for improvement in both the diagnosis and management of prostate cancer,” said study coauthor Michael Scott, BYU professor of civil and environmental engineering. “We’re using computer modeling to capture the behavior of prostate tumor growth which will hopefully lead to minimally invasive predictive procedures which can be used in clinical practice.”

Current diagnosis methods include invasive biopsy procedures which too often lead to patients being over-treated or under-treated. Complicating matters is the fact that prostate cancer can remain undiagnosed because early stages of the disease may not produce symptoms until a tumor is either very large or has invaded other tissues.

The new system could lead to both earlier diagnosis and less invasive testing. It’s a promising development given prostate cancer is the second most common cancer among men worldwide, responsible for 308,000 deaths in 2012 and estimated to take 26,120 lives in the U.S. alone in 2016.

Scott, and fellow BYU professor Kevin Tew teamed up with colleagues at the University of Coruna, UT-Austin and Carnegie Mellon for the study. The personalized tumor growth simulations leveraged the high-performance computing resources available through BYU’s Fulton Supercomputing Lab.

Scott said the research is still in its infancy and extensive validation and refinement of the model must occur before it is ready for clinical application. That said, “it’s likely that these types of models will eventually turn up in medical practice,” he added.

“We are entering an age where we will see the emergence of tools which leverage computation to improve diagnosis of disease,” Scott said. “And we’re not the only people working in this area — it’s rapidly growing.”


Story Source:

Materials provided by Brigham Young University. Original written by Todd Hollingshead. Note: Content may be edited for style and length.

Read on ScienceDaily: Brigham Young University. “Computer modeling could lead to new method for detecting, managing prostate cancer.” ScienceDaily. ScienceDaily, 22 November 2016. www.sciencedaily.com/releases/2016/11/161122080748.htm.


High-intensity focused ultrasound or HIFU has many proven advantages over traditional treatment modalities for prostate disease. HIFU is most effective for patients with early stage prostate cancer where the cancer is localized to the prostate. Visit our website to learn more: http://www.californiahifu.com/ #prostatecancer #HIFU #prostate #menshealth

By | December 6th, 2016|HIFU, News, Prostate Cancer|0 Comments

One year following FDA approval California HIFU is Giving Prostate Cancer Patients Hope for a Healthy Future

Santa Rosa Urologist Dr. Michael Lazar celebrates California HIFU’s first anniversary with look back at October 2015 when HIFU received approval from Food and Drug Administration for use in the U.S.

High-intensity focused ultrasound (HIFU) is a technology that targets cancer cells with precision in a one to four-hour procedure that has little or no side effects, provides a remarkably quick recovery rate, and gives men diagnosed with prostate cancer a less invasive option over surgery or radiation.

“The oncological results for HIFU is comparable to more traditional prostate cancer treatments including radical surgery or radiation. But the side effects for HIFU patients have proven to be much less debilitating than more radical procedures,” says Dr. Lazar. “For example, if the HIFU procedure is performed in the morning, a patient is typically ambulatory by dinnertime and can often return to normal activity within a few days without the use of pain-killers.”

HIFU Background

Sonablate was the first focused ultrasound ablation device to receive regulatory authorization from the FDA for prostate cancer. Although relatively new to the U.S. Sonablate® technology has been used around the world on more than 15,000 patients in over 30 countries for 15 years. Approximately 4,000 U.S. men have received HIFU treatment outside the U.S. prior to FDA approval.

Recognizing its potential as a less invasive treatment option with the ability to eliminate prostate cancer while preserving patient quality of life, Dr. Lazar became one of the early advocates for HIFU. Once fully trained in the technology, he began treating U.S. prostate cancer patients in Mexico beginning in 2007. He performed outpatient procedures at a U.S. Joint Commission approved bilingual hospital in Mexico – helping to bring this innovative prostate cancer treatment to hundreds of men diagnosed with the disease. During that time Dr. Lazar also served as a HIFU instructor for other physicians and is now actively training doctors in San Francisco.

Immediately following FDA approval in 2015, HIFU Prostate Services (HPS) became the first company to establish centers in the United States offering Sonablate HIFU technology to prostate cancer patients. Serving as Medical Director for HPS Dr. Lazar simultaneously founded California HIFU to provide HIFU services in the San Francisco area, the first such facility on the west coast. Since that time HIFU using Sonablate® technology has become available in more than 40 locations across the nation.

How Patients Respond to HIFU

https://youtu.be/oNt1g6p5nOE

Dr. Lazar’s HIFU Patients Share Their Experiences

For patients with prostate cancer, HIFU treatment is most effective in the early stages, where it is localized to the prostate. It is performed on an out-patient basis in just a few hours. The procedure preserves healthy tissue and nerves, so urine flow and erectile function is maintained in a high percent of cases, as compared to radical surgery or radiation.

Several of Dr. Lazar’s HIFU patients recently came together to tell their stories and to share their personal experience with prostate cancer in a poignant new video titled California HIFU Patient Stories video. “The biggest benefit of HIFU for me was lack of risk compared to the other options,” says one patient. The results “have been exactly as Dr. Lazar described it to me,” another patient says. “I think I would be a much more crippled individual with other forms of treatment,” says another, adding “…. there’s very little worry involved in this procedure.” For more patient stories visit the California HIFU YouTube channel.

About Dr. Lazar

Dr. Lazar is part of Northern California Medical Associates and operates California HIFU in Santa Rosa. He is the medical director of HIFU Prostate Services, LLC, a leading provider of minimally-invasive prostate cancer treatments using High Intensity Focused Ultrasound (HIFU). Dr. Lazar is also a clinical partner with HPS with the HIFU San Francisco Surgery Center of Excellence, a state-of-the-art facility that is convenient to hotels and the airport.  For more information about Dr. Lazar, HIFU treatment for prostate cancer visit the HIFU website or to make an appointment call: (707) 546-5553.

Researchers discover three novel intrinsic subtypes of prostate cancer

pipet-1440965In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO). Findings represent a step toward the implementation of personalized medicine in prostate cancer care.

To diagnose and determine treatment for prostate cancer, clinicians consider many factors, including a digital rectal exam, the prostate specific antigen (PSA) level in a patient’s blood and prostate tumor biopsy results. Molecular subtyping of tumor cells allows oncologists to individualize care and tailor treatment based on the actual biology of each patient’s individual disease.

“Tumors that appear similar under a microscope can behave very differently, from a clinical standpoint,” said Daniel E. Spratt, MD, lead author of the study and Chief of the Genitourinary Radiotherapy Program at the University of Michigan in Ann Arbor, Michigan. “One promise of genomic analyses is to elucidate subtypes of cancer based on the genetics of the tumor rather than merely how they look or what size they are.”

To identify genomic profiles for prostate cancer, researchers analyzed RNA expression patterns in 4,236 samples from nine separate groups of men treated with radical prostatectomy for localized prostate cancer. In an effort to create “intrinsic” subtypes specific to the cancer itself rather than the associated surrounding tissue, data were refined to remove non-tumor genes from the training (i.e., identification not validation) dataset. Through K-median clustering analysis, researchers identified three molecular subtypes of prostate cancer that could be characterized through a profile of 100 distinct genes, named the Prostate Cancer 100 (PC100) by study investigators.

“We were surprised to find that prostate cancer subtyped into only three very distinct subtypes,” said Dr. Spratt. “We knew that primary prostate cancer was a relatively quiet tumor, genomically, but similar cancers that are endocrine-driven, like breast cancer, have been shown to be able to be clustered into a finite number of subtypes.”

Researchers validated the subtypes across six additional retrospective cohorts, representing a variety of RNA sequencing platforms and tissue storage methods, and two prospective cohorts comprising 2,610 patients. The intrinsic subtypes were associated with androgen receptor (AR) activity, expression of the ERG oncogene and other known drivers of prostate tumor growth and progression, but researchers did not find a link from mutations or genetic rearrangements to the subtypes.

Rates of distant metastasis-free survival (DMFS) at ten years varied significantly among the three subtype groups. DMFS rates were 57.1 percent for subtype A, 64.4 percent for subtype B, and 73.6 percent for subtype C (B vs. A: Cox Hazard Ratio (HR), 1.31, p = 0.02; C vs. A: HR, 1.65, p = 0.0001). After controlling for clinocopathologic variables, the profile remained independently associated with DMFS (B vs. A: Cox HR, 1.31, p = 0.026; C vs. A: HR, 1.33, p = 0.024). Additionally, multivariate interaction analysis determined that subtypes B and C shared a significant correlation with response to post-operative radiation therapy (RT) (Wald p = 0.0016).

“We have discovered and independently validated a highly stable 100-gene intrinsic molecular profile of prostate cancer that is both prognostic and predictive for radiation therapy,” said Dr. Spratt. “We believe that these subtypes reflect truly distinctive underlying biology and that this work represents a significant advance in our understanding of prostate cancer biology. Moreover, our findings identify numerous genes and enriched biologically active pathways in prostate cancer that have been underappreciated to date but may be potential targets to improve cure rates in this disease by developing new targeted therapies.”


Story Source:

Materials provided by American Society for Radiation Oncology (ASTRO). Note: Content may be edited for style and length.


American Society for Radiation Oncology (ASTRO). “Three novel intrinsic subtypes of prostate cancer identified.” ScienceDaily. ScienceDaily, 26 September 2016. www.sciencedaily.com/releases/2016/09/160926100610.htm.
By | November 1st, 2016|Dr. Michael Lazar, HIFU, News, Prostate Cancer|0 Comments

California HIFU Patients Tell Their Stories

California HIFU Patients Tell Their Stories

– NEW VIDEO – Cancer patients who have opted for High Intensity Focused Ultrasound (HIFU), a noninvasive prostate cancer treatment offered by Dr. Michael Lazar of California HIFU, speak out about why they chose HIFU over other options, and what they have experienced as a result. Click on the video below to watch.

About California HIFU

High-intensity focused ultrasound or HIFU has many proven advantages over traditional treatment modalities for prostate disease. For more information about HIFU treatment or to make an appointment call: (707) 546-5553 or visit our website: www.californiahifu.com
By | October 10th, 2016|HIFU, News|0 Comments

How early can prostate cancer be detected?

Screening is testing to find cancer in people before they have symptoms. For some types of cancer, screening can help find cancers at an early stage, when they are likely to be easier to treat. According to the American Cancer Society, prostate cancer can often be found before symptoms arise by testing the amount of prostate-specific antigen (PSA) in a man’s blood. Another way to find prostate cancer is the digital rectal exam (DRE), in which the doctor puts a gloved, lubricated finger into the rectum to feel the prostate gland.

If the results of either one of these tests are abnormal, further testing is often done to see if a man has cancer. If prostate cancer is found as a result of screening with the PSA test or DRE, it will probably be at an earlier, more treatable stage than if no screening were done.There is no question that screening can help find many prostate cancers early, but there are still questions about whether the benefits of screening outweigh the risks for most men. There are clearly both pros and cons to the prostate cancer screening tests in use today.At this time, the American Cancer Society (ACS) recommends that men thinking about getting screened for prostate cancer should make informed decisions based on available information, discussion with their doctor, and their own views on the possible benefits, risks, and limits of prostate cancer screening. To learn more about prostate cancer screening and the current American Cancer Society’s screening guidelines, see Prostate Cancer Prevention and Early Detection.

High-intensity focused ultrasound or HIFU has many proven advantages over traditional treatment modalities for prostate disease. For more information about HIFU treatment or to make an appointment call: (707) 546-5553.

By | August 9th, 2016|Dr. Michael Lazar, HIFU, News|0 Comments

California HIFU is the Right Choice for Prostate Cancer Treatment

For the past five years, Chris Lockheed’s PSA numbers had been going up. Then, last November, a biopsy revealed that he had two tumors on his prostate. Chris, 68, started doing research into what kind of options for treatment were available to him. When a radiation specialist in Rohnert Park told him about Dr. Michael Lazar and the HIFU procedure, he did more homework. He found that Dr. Lazar had done hundreds of these procedures in Puerto Vallarta, and the treatment was given FDA approval last October.

“Dr. Lazar explained everything, and he’s done over 300 of the procedures, that’s why I went to him. I felt very confident. I looked at all of the choices and said ‘this is for me’.” In March, Chris, who lives in Santa Rosa, drove down to the San Francisco Surgery Center for the three
hour outpatient procedure. Afterwards, feeling no side affects, Chris got some take-out food and drove home. Chris also mentioned he needed no
pain medication. The only side affect he had was the catheter, which was “a little irritating.”

Chris is a pet supplies representative, and his travels take him from Marin to Eureka. He is also a professional drummer who has recorded with Epic, CBS/Columbia, Capitol, Universal, and independent labels. “To be careful, I took a week off from work, but I was still active.” A week after the procedure, he went back to Dr. Lazar to have the catheter taken out.

“There was no leaking urine issues or erectile dysfunction, everything was fine. After getting the catheter out, everything was totally normal.” A
week after the procedure Chris was back at work, drumming on the weekend, and working in the yard. Chris is so satisfied with the results he has been recommending Dr. Lazar and the HIFU procedure to other men as an option to prostate surgery.

Lazar testimonial jpg

For more information about HIFU treatment or to make an appointment call: (707) 546-5553.

Prostate cancer news: Laser ablation becomes viable treatment option

Prostate cancer news: Laser ablation becomes viable treatment option

lazer beamProstate cancer patients may soon have a new option to treat their disease: laser heat. UCLA researchers have found that focal laser ablation – the precise application of heat via laser to a tumor – is both feasible and safe in men with intermediate risk prostate cancer.

The Phase 1 study found no serious adverse effects or changes in urinary or sexual function six months after the procedure. The technique uses magnetic resonance imaging, or MRI, to guide the insertion of a laser fiber into cancerous tumors. When heated, the laser destroys the cancerous tissue.

A follow-up study, presented in a poster presentation at the American Urology Association meeting in May, showed the potential to transfer this treatment for the first time into a clinic setting, using a special device (Artemis) that combines both MRI and ultrasound for real-time imaging. The Artemis device arrived at UCLA in 2009. Since then, 2000 image-fusion biopsies have been performed – the most in the U.S. – and this large experience has paved the way for treatment to be done in the same way.

If the laser technique, known as MRI-guided focal laser ablation, proves effective in further studies — especially using the new MRI-ultrasound fusion machine — it could improve treatment options and outcomes for men treated for such cancers, said study senior author Dr. Leonard Marks, a professor of urology and director of the UCLA Active Surveillance Program. Historically, prostate cancer has been treated with surgery and radiation, which can result in serious side effects such as erectile dysfunction and urinary incontinence.

“Our feeling was that if you can see prostate cancer using the fusion MRI and can put a needle in the spot to biopsy it, why not stick a laser fiber in the tumor the same way to kill it,” Marks said. “This is akin to a lumpectomy for breast cancer. Instead of removing the whole organ, target just the cancer inside it. What we are doing with prostate cancer now is like using a sledgehammer to kill a flea.”

Read the full story here …

In the U.S. HIFU with the Sonablate® 500 has many proven advantages over traditional treatment modalities for prostate disease. For more information about HIFU treatment or to make an appointment call: (707) 546-5553.
By | July 14th, 2016|Dr. Michael Lazar, HIFU|0 Comments

Prostate cancer news: Laser ablation becomes viable treatment

Prostate cancer patients may soon have a new option to treat their disease: laser heat. UCLA researchers have found that focal laser ablation – the precise application of heat via laser to a tumor – is both feasible and safe in men with intermediate risk prostate cancer.

An illustration of laser ablation to treat prostate cancer.

The Phase 1 study found no serious adverse effects or changes in urinary or sexual function six months after the procedure. The technique uses magnetic resonance imaging, or MRI, to guide the insertion of a laser fiber into cancerous tumors. When heated, the laser destroys the cancerous tissue.

A follow-up study, presented in a poster presentation at the American Urology Association meeting in May, showed the potential to transfer this treatment for the first time into a clinic setting, using a special device (Artemis) that combines both MRI and ultrasound for real-time imaging. The Artemis device arrived at UCLA in 2009. Since then, 2000 image-fusion biopsies have been performed – the most in the U.S. – and this large experience has paved the way for treatment to be done in the same way.

If the laser technique, known as MRI-guided focal laser ablation, proves effective in further studies — especially using the new MRI-ultrasound fusion machine — it could improve treatment options and outcomes for men treated for such cancers, said study senior author Dr. Leonard Marks, a professor of urology and director of the UCLA Active Surveillance Program. Historically, prostate cancer has been treated with surgery and radiation, which can result in serious side effects such as erectile dysfunction and urinary incontinence.

“Our feeling was that if you can see prostate cancer using the fusion MRI and can put a needle in the spot to biopsy it, why not stick a laser fiber in the tumor the same way to kill it,” Marks said. “This is akin to a lumpectomy for breast cancer. Instead of removing the whole organ, target just the cancer inside it. What we are doing with prostate cancer now is like using a sledgehammer to kill a flea.”

Read the full story here …

In the U.S. HIFU with the Sonablate® 500 has many proven advantages over traditional treatment modalities for prostate disease. For more information about HIFU treatment or to make an appointment call: (707) 546-5553.
By | July 12th, 2016|HIFU, News|0 Comments

Mayo Clinic: Tips on Prostate cancer prevention

There’s no proven prostate cancer prevention strategy. But one way to reduce the risk of prostate cancer is by making healthy choices, such as exercising and eating a healthy diet. Study results often conflict with each other and most studies aren’t designed to definitively prove whether something prevents prostate cancer. As a result, no clear ways to prevent prostate cancer have emerged.

In general, doctors recommend that men with an average risk of prostate cancer make choices that benefit their overall health if they’re interested in prostate cancer prevention.

Choose a healthy diet

There is some evidence that choosing a healthy diet that’s low in fat and full of fruits and vegetables may contribute to a lower risk of prostate cancer, though this hasn’t been proved concretely.

good-food-1328410

Choose a low-fat diet. Foods that contain fats include meats, nuts, oils and dairy products, such as milk and cheese.

In some studies, men who ate the highest amount of fat each day had an increased risk of prostate cancer. While this association doesn’t prove that excess fat causes prostate cancer, reducing the amount of fat you eat each day has other proven benefits, such as helping you control your weight and helping your heart.

To reduce the amount of fat you eat each day, limit fatty foods or choose low-fat varieties. For instance, reduce the amount of fat you add to foods when cooking, select leaner cuts of meat, and choose low-fat or reduced-fat dairy products.

Read the full story here …

HIFU with the Sonablate® 500 has many proven advantages over traditional treatment modalities for prostate disease. For more information about HIFU treatment or to make an appointment call: (707) 546-5553.

By | June 28th, 2016|Dr. Michael Lazar, HIFU, News, Prostate Cancer|0 Comments

Focal Therapy For Prostate Cancer

hifu mini article cropped-logo-square.jpgFocal therapy, often referred to as a “male lumpectomy,” is a general term for a variety of noninvasive techniques for destroying small tumors inside the prostate while leaving the gland intact and sparing most of its normal tissue

As technology has advanced, physicians now have the ability to diagnose patients with prostate cancer earlier which means that often times tumors within the prostate are small and contained to the prostate.

Advanced imaging techniques, allow doctors to pinpoint exactly where the tumor within the prostate is located using multi-parametric MRI and UroNav fusion biopsies, enabling them to target only the tumor within the prostate, leaving other tissue unharmed.

Focal therapy is being studied all over the world because of the large potential for reducing side effects such as urinary incontinence and erectile dysfunction. Additionally, due to the noninvasive nature of focal therapy, treatment and recovery times are dramatically reduced.

Read this article on HIFU Prostate Services.

For more information about HIFU treatment which is now available in San Francisco, or to make an appointment call: (707) 546-5553. Visit us online to learn more at: www.californiahifu.com.